Sorafenib Monotherapy in Patients With Metastatic Renal Cell Cancer: A Phase Ii Intra-Patient Dose- Escalation Study

Amato, Robert J.; Harris, Patricia; Dalton, Martin L.; Khan, Muhammad; Zhai, Jiahong; Brady, John C.; Jac, J.; Alter, Roxanne; Hauke, R. J.

doi:10.1016/s1569-9056(08)60698-3

Search citation statements

Order By: Relevance

Paper Sections

Select...

Sorafenib1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2008

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dose escalation of sorafenib was explored in a phase 2 study in 44 patients, who were commenced on 400mg BD for 28 days and then escalated to 600mg BD if the toxicity profile allowed [66]. Dose escalation was tolerated by 41 patients.…”

Section: Sorafenibmentioning

confidence: 99%

Targeted Therapies in the Treatment of Renal Cell Carcinoma

Pezaro

Davis

2008

CMC

View full text Add to dashboard Cite

The management of renal cell carcinoma (RCC) has undergone rapid and radical evolution over the last few years. An improved understanding of the underlying biology of RCC has led to the approval of several new therapies directed against specific and relevant biological targets, so-called "targeted therapies." These highly effective treatments are now entering routine use, however many questions still remain as to how best to use these agents and integrate them into the broader therapeutic armamentarium. This review summarizes the major published clinical trials of the new agents, discusses the controversies and research questions that have arisen as a result, and considers some of the issues that remain.

show abstract

Section: Sorafenibmentioning

confidence: 99%